55 related articles for article (PubMed ID: 7591889)
21. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
Dattoli M; Wallner K; True L; Cash J; Sorace R
Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673
[TBL] [Abstract][Full Text] [Related]
22. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
[TBL] [Abstract][Full Text] [Related]
23. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.
Beyer DC; McKeough T; Thomas T
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1299-305. PubMed ID: 15817331
[TBL] [Abstract][Full Text] [Related]
24. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
[TBL] [Abstract][Full Text] [Related]
25. The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases.
Moul JW; Connelly RR; Perahia B; McLeod DG
J Urol; 1998 Mar; 159(3):935-40. PubMed ID: 9474187
[TBL] [Abstract][Full Text] [Related]
26. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
Michalski JM; Winter K; Purdy JA; Parliament M; Wong H; Perez CA; Roach M; Bosch W; Cox JD
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):706-13. PubMed ID: 15936549
[TBL] [Abstract][Full Text] [Related]
27. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
28. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy.
Zelefsky MJ; Marion C; Fuks Z; Leibel SA
J Urol; 2003 Nov; 170(5):1828-32. PubMed ID: 14532785
[TBL] [Abstract][Full Text] [Related]
29. Correlation of prostate-specific acid phosphatase and prostate-specific antigen immunocytochemistry with survival in prostate carcinoma.
Hammond ME; Sause WT; Martz KL; Pilepich MV; Asbell SO; Rubin P; Myers RP; Farrow GM
Cancer; 1989 Feb; 63(3):461-6. PubMed ID: 2463874
[TBL] [Abstract][Full Text] [Related]
30. Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86-10.
Torres-Roca JF; DeSilvio M; Mora LB; Khor LY; Hammond E; Ahmad N; Jove R; Forman J; Lee RJ; Sandler H; Pollack A
Urology; 2007 Mar; 69(3):505-9. PubMed ID: 17382154
[TBL] [Abstract][Full Text] [Related]
31. The relation of prostatic acid phosphatase and prostate specific antigen with tumour grade in prostatic adenocarcinoma: an immunohistochemical study.
Ersev A; Ersev D; Turkeri L; Ilker Y; Simsek F; Kullu S; Akdas A
Prog Clin Biol Res; 1990; 357():129-34. PubMed ID: 1699237
[TBL] [Abstract][Full Text] [Related]
32. The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy.
Zagars GK; Ayala AG; von Eschenbach AC; Pollack A
Int J Radiat Oncol Biol Phys; 1995 Jan; 31(2):237-45. PubMed ID: 7836075
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical prostatic acid phosphatase level as a prognostic factor of prostatic carcinoma.
Sakai H; Shiraishi K; Minami Y; Yushita Y; Kanetake H; Saito Y
Prostate; 1991; 19(3):265-72. PubMed ID: 1946042
[TBL] [Abstract][Full Text] [Related]
34. Role of immunocytochemistry in diagnosis of prostatic neoplasia by fine needle aspiration biopsy.
Katz RL; Raval P; Brooks TE; Ordóñez NG
Diagn Cytopathol; 1985; 1(1):28-32. PubMed ID: 2424683
[TBL] [Abstract][Full Text] [Related]
35. Relationship of prostatic acid phosphatase localization in human prostate by a monoclonal antibody with the Gleason grading system.
Sinha AA; Gleason DF; Wilson MJ; Wick MR; Reddy PK; Blackard CE
Prostate; 1988; 13(1):1-15. PubMed ID: 2458582
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors in carcinoma of the prostate--analysis of RTOG study 75-06.
Pilepich MV; Krall JM; Sause WT; Johnson RJ; Russ HH; Hanks GE; Perez CA; Zinninger M; Martz KL
Int J Radiat Oncol Biol Phys; 1987 Mar; 13(3):339-49. PubMed ID: 3558026
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical identification of prostatic acid phosphatase: correlation of tumor grade with acid phosphatase distribution.
Bates RJ; Chapman CM; Prout GR; Lin CW
J Urol; 1982 Mar; 127(3):574-80. PubMed ID: 6174741
[TBL] [Abstract][Full Text] [Related]
38. Radiation therapy in the management of localized carcinoma of the prostate: a preliminary report.
McGowan DG
Cancer; 1977 Jan; 39(1):98-103. PubMed ID: 401678
[TBL] [Abstract][Full Text] [Related]
39. The immunohistochemical detection of prostatic acid phosphatase: its possibilities and limitations in tumour histochemistry.
Jöbsis AC; De Vries GP; Meijer AE; Ploem JS
Histochem J; 1981 Nov; 13(6):961-73. PubMed ID: 6175605
[TBL] [Abstract][Full Text] [Related]
40. [Studies on acid phosphatase in prostatic cancer. I. Acid phosphatase isoenzymes of various tissue extracts (author's transl)].
Morishita N
Nihon Hinyokika Gakkai Zasshi; 1980 Apr; 71(4):319-23. PubMed ID: 7401414
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
